[ad_1] Novartis agreed to purchase the rights of a drug to treat a skin disease to developers Galapagos NV and MorphoSys AG in a transaction that could reach 1,000 million US dollars …
Read More »[ad_1] Novartis agreed to purchase the rights of a drug to treat a skin disease to developers Galapagos NV and MorphoSys AG in a transaction that could reach 1,000 million US dollars …
Read More »